New antibiotics

Amanda L. Hurst; Kari A. Neemann; Archana Chatterjee

doi:10.1016/B978-0-323-85730-7.00036-9

New antibiotics

Amanda L. Hurst, Kari A. Neemann, Archana Chatterjee

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Scopus citations

Abstract

The threat of drug-resistant infections has been mounting the past two decades, making new antibiotic development to treat those infections increasingly important. National organizations pushed to make new antibiotic availability a priority. Since 2010, there have been 16 new antibiotics brought to market, all of which cover emerging, threatening, and/or drug-resistant pathogens. The legislative and funding changes resulting from the focus on making combating drug resistance a priority made this possible. This chapter provides information on each of the new antibiotics including mechanism of action, dosing, adverse effects, uses, and key studies associated with their approval.

Original language	English (US)
Title of host publication	Viral, Parasitic, Bacterial, and Fungal Infections
Subtitle of host publication	Antimicrobial, Host Defense, and Therapeutic Strategies
Publisher	Elsevier
Pages	675-698
Number of pages	24
ISBN (Electronic)	9780323857307
ISBN (Print)	9780323898003
DOIs	https://doi.org/10.1016/B978-0-323-85730-7.00036-9
State	Published - Jan 1 2022

Keywords

Antibiotic pipeline
Drug resistance
Drug-resistant bacteria
New antibiotics

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-323-85730-7.00036-9

Cite this

@inbook{26a35a2984d746c4815904067c69cc7f,

title = "New antibiotics",

abstract = "The threat of drug-resistant infections has been mounting the past two decades, making new antibiotic development to treat those infections increasingly important. National organizations pushed to make new antibiotic availability a priority. Since 2010, there have been 16 new antibiotics brought to market, all of which cover emerging, threatening, and/or drug-resistant pathogens. The legislative and funding changes resulting from the focus on making combating drug resistance a priority made this possible. This chapter provides information on each of the new antibiotics including mechanism of action, dosing, adverse effects, uses, and key studies associated with their approval.",

keywords = "Antibiotic pipeline, Drug resistance, Drug-resistant bacteria, New antibiotics",

author = "Hurst, {Amanda L.} and Neemann, {Kari A.} and Archana Chatterjee",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-85730-7.00036-9",

language = "English (US)",

isbn = "9780323898003",

pages = "675--698",

booktitle = "Viral, Parasitic, Bacterial, and Fungal Infections",

publisher = "Elsevier",

}

TY - CHAP

T1 - New antibiotics

AU - Hurst, Amanda L.

AU - Neemann, Kari A.

AU - Chatterjee, Archana

PY - 2022/1/1

Y1 - 2022/1/1

N2 - The threat of drug-resistant infections has been mounting the past two decades, making new antibiotic development to treat those infections increasingly important. National organizations pushed to make new antibiotic availability a priority. Since 2010, there have been 16 new antibiotics brought to market, all of which cover emerging, threatening, and/or drug-resistant pathogens. The legislative and funding changes resulting from the focus on making combating drug resistance a priority made this possible. This chapter provides information on each of the new antibiotics including mechanism of action, dosing, adverse effects, uses, and key studies associated with their approval.

AB - The threat of drug-resistant infections has been mounting the past two decades, making new antibiotic development to treat those infections increasingly important. National organizations pushed to make new antibiotic availability a priority. Since 2010, there have been 16 new antibiotics brought to market, all of which cover emerging, threatening, and/or drug-resistant pathogens. The legislative and funding changes resulting from the focus on making combating drug resistance a priority made this possible. This chapter provides information on each of the new antibiotics including mechanism of action, dosing, adverse effects, uses, and key studies associated with their approval.

KW - Antibiotic pipeline

KW - Drug resistance

KW - Drug-resistant bacteria

KW - New antibiotics

UR - http://www.scopus.com/inward/record.url?scp=85150151149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150151149&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-85730-7.00036-9

DO - 10.1016/B978-0-323-85730-7.00036-9

M3 - Chapter

AN - SCOPUS:85150151149

SN - 9780323898003

SP - 675

EP - 698

BT - Viral, Parasitic, Bacterial, and Fungal Infections

PB - Elsevier

ER -

New antibiotics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this